Coave Therapeutics

A clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases.

Launch date

Feb 2014

Employees

Market cap

Enterprise valuation

Company register number 800830721

Paris Île-de-France (HQ)

Revenues, earnings & profits over time

EUR	2015	2016	2017
Profit	(<1m)	1.6m	3.3m

Date	Investors	Amount	Round
-	Turenne Capital Eurazeo Théa Open Innovation	N/A	-
Feb 2014	Ouest Valorisation	N/A	Support Program
Feb 2014	Ouest Valorisation French National Centre for Scientific Research Nantes University	N/A	Spinout
Jan 2015	Bpifrance	€450k	Seed
Jul 2016*	Omnes Capital GO Capital	€4.0m	Series A
Nov 2017	GO Capital Pontifax Funds Sham FundPlus Kurma Partners	€19.0m	Series B
Sep 2018	V-Bio Ventures	€22.5m	Series B
Jul 2021*	Omnes Capital GO Capital Seroba Life Sciences V-Bio Ventures Sham Kurma Partners ADIN EureKARE	$38.9m	Series B
Feb 2024*	The ALS Association	N/A	Grant
Total Funding		AUD138m

Tech stackLearn more about the technologies and tools that this company uses.

Financials